

Ignyta (RXDX : US\$6.92)

Ignyta tumbles 31% in 2014

Ignyta Inc, NASDAQ's 34th largest healthcare-products company by market cap, has now tumbled US\$3.10 (or 30.9%) year to date in 2014 to close at US\$6.92. The volume YTD has been 0.7 times average trading of 45,370 shares. Compared with the NASDAQ-100 Index which rose 295.6 points (or 7.6%) in the quarter, this represented a relative price change of -23.0%. In 2014 the market cap has declined US\$48.2 million.

Introduction

We are currently bearish on this stock, both in the short-term based on technical indicators, as well as in the long-term based on fundamental metrics

What makes us most bearish on the stock is the following:

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.5. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.
- The price to 200-day MAP ratio is 0.77, a bearish indicator.
- In the last three months the number of falls outnumbered rises 29:19 or 1.53:1.

However, there are some reasons why some in the market are more bullish on the stock:

- Amongst stocks that are shorted, it was in the bottom quartile as a percentage of stock shorted, suggesting that there are fewer confident bears of the stock.
- "A stock price down to at least two-thirds of tangible book value per share"; the price is 0.61 times tangible book value per share of \$US11.26.

Stock Summary

Sector	Healthcare-Products
Market Cap	US\$135.5 million
Shares Outstanding	19,576,255
ISIN	US4517311035
Relative Strength (3 mo)	19

MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	6.9	135.5 million

Analysis

Bullish Signals

- The price is at a discount of 3.9% to the 1-month volume weighted average price of US\$7.20, which may appeal as a value proposition.
- The Price/MAP of 0.77 for RXDX is higher than the Price/MAP for the NASDAQ-100 Index of 0.4.
- In the NASDAQ Short Selling market of 2425 stocks, short selling as a % of issued shares ranked 2046th and within the bottom quartile of stocks. This means it was lower than market average of 0.55%, a bullish indicator.
- The current short volume is 0.2 times its own historical average of 0.03%. It plummeted 44.7% from the previous day, plummeted 85.1% from a week ago and plummeted 50.1% from a month ago, a significant bullish indicator.

Undervaluation:

- The company is cash rich with Cash to Market Capitalisation at 38.2%.

Other Bullish Signals:

- Return on Assets is negative but improving in recent years.

Annual Trend:

[Year ended, all figures in %]:

Year	ROE	ROA	ROCE
Aug 13	-250	-100	-
Dec 12	-28.1	-23.5	-25.3


Also, the following criteria set by Benjamin Graham:

- "A stock price down to at least two-thirds of tangible book value per share"; the price is 0.61 times tangible book value per share of \$US11.26.
- "Current ratio of two or more"; current assets are 34.3 times current liabilities.

Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Volatility %	0.3	In Top 6%
Cash to MCap %	38.2	In Top 7%

Revenue Share Healthcare-Products



Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 29:19 or 1.53:1.
- In the last 19 trading sessions there has been a net decline of 5.59%; the stock has retreated twelve times and the biggest one day decline was 4.6% on Oct 22.
- In the NASDAQ market of 2,401 stocks traded today, the stock has a 6-month relative strength of 33 which means it has underperformed 67.0% of the market.
- Also, the relative strength percentile is falling at 33 for 6 months, 19 for 3 months and 12 for 1 month.
- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 6.94 minus the 26-day EMA of 7.06 is negative suggesting a bearish signal. Both the 12-day EMA as well as the 26-day EMA are falling, another bearish signal.
- The price to 200-day MAP ratio is 0.77, a bearish indicator. The 200-day MAP has decreased to US\$9.0. A decrease is another bearish indicator.

Overvaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.5. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

Other Bearish Signals:

The stock has a score of merely 1 out of 9 set by Joseph Piotroski [pass mark >=5]:

Reduction in total shares on issue.

Analysis (continued)

Bearish Indicators and Rank in Market:


Description	Value	Rank In Market
Turnover in Quarter	US\$10.6 million	In Bottom Quartile
Price/MAP200	0.77	In Bottom Quartile
Price/MAP50	0.53	In Bottom 6%

Note

Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$135.5 million	In 3rd Quartile


YTD Comparison Stock Sector Index



Insider Trades



Turnover Rate & Turnover Period




Trailing 3 months

Turnover	US\$10.6 million
Volume	1,428,820
Volume Index (1 is avg)	0.5


Price Volume Trend: Trailing Quarter



Weekly Price Volume Dynamics (Last 12 Weeks)



Stock v Index (Trailing Year)



Price/Moving Average Price [P/MAP]



Reported Buying Selling by Insiders

Insider	Date	Transaction Type	No. of Shares	Price, US\$	Value, US\$
Chacko Jacob	Aug 19, 2014	Bought	1,540	7.53	11,596
Lim Jonathan E	Aug 15, 2014	Bought	5,000	7.6	38,000
Chacko Jacob	Aug 15, 2014	Bought	300	7.5	2,250

Company Overview

Regulatory Announcements

To view Recent Company Headlines, [click here](#)

November 01: Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014

October 02: Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014

October 01: Ignyta Secures \$31 Million Term Loan Facility from Silicon Valley Bank

September 28: Ignyta Announces Interim Data from RDX-101 Phase I Clinical Trial at 2014 ESMO Congress

September 25: Ignyta to Present at Livingston Securities Life Science Stakeholders Summit

September 17: Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders

September 15: Ignyta Announces RDX-101 Phase I Data Presentation at the 2014 ESMO Congress

To view 8-K other news for Ignyta, [click here](#)

October 14: Ignyta: Regulation FD Disclosure

October 01: Ignyta: Entry into a Material Definitive Agreement

September 29: Ignyta: Regulation FD Disclosure

August 04: Ignyta: Entry into a Material Definitive Agreement

Annual Report

To view Annual Report [click here](#)

Quarterly Report

To view Quarterly Report [click here](#)

Issued Capital


Based on 19,576,255 issued equity shares the market capitalisation is US\$135.5 million. It is NASDAQ's 21st largest Healthcare-Products company by total revenue.

The top thirteen shareholders hold 26.5% of the issued capital leaving a float of 73.5%.

Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Fmr LLC	1,567,709	8.01
Jpmorgan Chase & Co	926,959	4.74
Visium Asset Management Lp	833,000	4.26
Redmile Group LLC	600,000	3.06
Foresite Capital Management I LLC	500,000	2.55
Artal Group S.A.	300,000	1.53
Alyeska Investment Group L.P.	168,578	0.86
Balyasny Asset Management LLC	115,000	0.59
Wexford Capital Lp	100,000	0.51
Deutsche Bank Ag\	41,285	0.21
Total	5,152,531	26.32

Top 13 Institutional Holdings



Board and Management

Jonathan E. Lim CEO & Chairman & Director

Jonathan Lim is the Chairman, Chief Executive Officer and a co-founder of Ignyta, Inc., a portfolio company of City Hill Ventures, LLC, a health care investment firm he founded in December 2010. In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout, which was successfully sold in September 2012 to Bionomics Ltd (ASX:BNO) where he currently serves as a member of the Board of Directors. From May 2003 to December 2010, Dr. Lim was President, Chief Executive Officer, and a Director of Halozyne Therapeutics, Inc. (NASDAQ: HALO), where he led the company's growth from a privately held startup with 5 employees to a publicly traded company with 140 employees and peak market capitalization of nearly \$1 billion. Under his leadership, the company went public and raised \$300 million from financings and corporate partnerships with Roche and Baxter, achieved two U.S. FDA approvals, and built a deep pipeline of late stage clinical drug candidates. Dr. Lim's prior experience includes management consulting at McKinsey & Company, NIH Postdoctoral Fellowship at Harvard, and two years of general surgery residency at New York Hospital-Cornell. He has B.S. and M.S. degrees from Stanford, M.D. from McGill, and M.P.H. from Harvard.

Jacob Chacko CFO

Jacob Chacko brings to Ignyta a broad range of experience with financing, managing, and advising companies in the life sciences field. Dr. Chacko joined Ignyta in May 2014 from TPG Capital, a global private investment firm with approximately \$60 billion of assets under management, where he served as a Vice President focused primarily on healthcare and digital media since August 2008. At TPG, Dr. Chacko helped lead teams that successfully completed acquisitions having an aggregate value of over \$10 billion. He served on the boards of directors of RentPath and EnvisionRx, was an advisor to the audit committee of Par Pharmaceutical, and was a board observer to IMS Health and Quintiles Transnational. Prior to TPG, Dr. Chacko concurrently received his M.D. from UCLA and his M.B.A. from Harvard Business School, and was president of his class at both institutions. Prior to this, Dr. Chacko was a consultant serving healthcare clients at the management consulting firm, McKinsey & Company. Dr. Chacko received an M.Sc. in economic and social history from Oxford University, where he was a Marshall Scholar, and a B.A. in biology, B.S. in gerontology, and minor in health policy and management from the University of Southern California.

Alex Casdin Director

Alex Casdin is a private investor focused on the health care sector. From October 2011 through September 2012, he was the Chief Financial Officer of Sophiris Bio. Prior to Sophiris, he served as the Vice President, Finance of Amylin Pharmaceuticals, a position he held from 2009 to 2011. Prior to his position at Amylin, Mr. Casdin ran Casdin Advisors LLC, where he served as a strategic advisor to companies in the life sciences industry. Before founding Casdin Advisors, Mr. Casdin was the Chief Executive Officer and Portfolio Manager of Cooper Hill Partners, LLC, a healthcare investment fund. Mr. Casdin held previous positions at Pequot Capital Management and Dreyfus Corporation. Mr. Casdin earned his B.A. degree from Brown University and his M.B.A., Beta Gamma Sigma, from Columbia Business School.

Board and Management (continued)

Heiner Dreismann Director

Heiner Dreismann is highly regarded in the healthcare industry with over 26 years of experience. He serves on the boards of several innovative public and private diagnostic companies. Dr. Dreismann completed a successful career at Roche Group from 1985 to 2006 where he held several senior positions including President and CEO of Roche Molecular Systems, Head of Global Business Development at Roche Diagnostics and Member of Roche's Global Diagnostic Executive Committee. Dr. Dreismann earned a Master of Science in biology and a Doctor of Philosophy in microbiology/molecular biology from Westfaelische Wilhelms University in Muenster, Germany. He conducted his Post-Doctoral studies in microbial genetics at the Centre d'Etudes Nucleaires de Saclay, France. Dr. Dreismann is an active member of the in vitro diagnostics (IVD) industry community and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique.

James Bristol Director

James Bristol is a distinguished leader in the field of drug discovery and chemistry with over 32 years of experience in the industry. Under Dr. Bristol's leadership at Pfizer during the period of 2004 – 2006, Worldwide Discovery Research scientists at Pfizer produced more than 130 drug candidates in 11 therapeutic areas. Dr. Bristol has over 100 publications, abstracts, and patents in drug discovery programs related to a number of therapeutic areas with a focus on mechanistic biochemistry. For nearly a decade, Dr. Bristol has served as Editor in Chief of the American Chemistry Society (ACS) publication series, Annual Reports in Medicinal Chemistry. His other prior professional activities have included serving in elected officer positions in the ACS Division of Medicinal Chemistry (Secretary, Vice Chairman, Chairman), Board of Trustees of the Gordon Research Conferences, Chairman of the Gordon Conference on Medicinal Chemistry, Co-Chair Keystone Conference, Adjunct Professor of Medicinal Chemistry at the University of Michigan, and numerous invited lectureships. Dr. Bristol is a Senior Advisor to Frazier Healthcare Ventures, Chairman of the Board of Managers of Deciphera Pharmaceuticals, LLC, Chairman of the Strategic and Scientific Advisory Board for Sai Advantium Ltd, a member of the Polycystic Kidney Disease Foundation Drug Discovery Advisory Group, and an advisor to a select number of promising biopharmaceutical companies.

James Freddo Director

Dr. Freddo joined our Board of Directors in 2014. Previously Dr. Freddo was consulting to Ignyta as Consultant Chief Medical Officer. Dr. Freddo was formerly the Executive Vice President, Clinical Development and Chief Medical Officer for Ruga Corporation, a private oncology biopharmaceutical company. Prior to that, he was the Chief Medical Officer and Senior Vice President, Drug Development and a member of the Board of Directors at Anadys Pharmaceuticals, which was acquired by Roche in 2011. Prior to joining Anadys Pharmaceuticals, Dr. Freddo served at Pfizer in La Jolla, California, holding the positions of Vice President, Clinical Site Head and Development Site Head and, prior to that, Executive Director and leader of Oncology Clinical Development. Prior to joining Pfizer, Dr. Freddo held a variety of senior management positions at Wyeth-Ayerst Research, in the Oncology, Infectious Diseases and Transplantation Immunology therapeutic areas. He has also served as a member of the Board of Directors for InfuSystems, Inc., a public healthcare products and services company. Dr. Freddo received an M.D. degree from the University of North Carolina, Chapel Hill, completed his residency training at University of California, San Diego and returned to Chapel Hill for his fellowship training in gynecologic oncology.

Board and Management (continued)

Zachary Hornby Chief Operating Officer

Zachary Hornby brings a dozen years of life sciences business experience to Ignyta. Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics where he was responsible for pharmaceutical partnerships and non-dilutive funding. Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX) and TKT (now Shire Human Genetic Therapies), and was a life sciences consultant at L.E.K. Consulting. Mr. Hornby is a director of Independa, Inc. Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.

Matt Onaitis Company Secretary

Matt Onaitis brings a wealth of public company general counsel experience to Ignyta. Prior to joining Ignyta, Mr. Onaitis was General Counsel of Trius Therapeutics, Inc. from May 2013 through its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis remained with Cubist assisting with the integration through December 2013. Mr. Onaitis was Senior Vice President, General Counsel and Secretary at Somaxon Pharmaceuticals, Inc. from May 2006 through Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Prior to Somaxon, Mr. Onaitis served as Associate General Counsel at Biogen Idec Inc., as Director, Legal Affairs at Elan Corporation plc, and in private practice specializing in corporate and commercial law. Mr. Onaitis is a director of SNP Bio, Inc. Mr. Onaitis holds a J.D. from Stanford Law School and a B.S. in mechanical engineering from Carnegie Mellon University.

Tony Shuber Vice President

Tony Shuber, an accomplished molecular biologist and inventor with more than 24 years of experience developing commercial diagnostics, joined Ignyta Operating as Vice President, Chief Technology Officer in March 2014. Prior to joining us, Mr. Shuber was a Co-Founder of Predictive Biosciences, Inc. and served as its Chief Technology Officer. Mr. Shuber served as Exact Sciences Corp.'s Executive Vice President and Chief Technology Officer from January 2003 to March 2006 and also as its Senior Vice President since April 2001. He also served as Exact Sciences' Vice President of Molecular Biology from January 1998 to April 2001. From October 1993 to June 1996, Mr. Shuber served as Senior Scientist and Manager of the Technical Development Laboratory for Genzyme Corporation. From 1983 to 1989, Mr. Shuber served as a Research Scientist at Genetics Institute. Mr. Shuber holds a B.S. and M.S. degree in Biology from Marquette University.

Financial Results (Quarterly)

30 June, 2014

INCOME STATEMENT

Currency in USD	2014-06-30	2013-06-30	Change %
Revenue	150,000		
Expenses			
Research and development	3,575,787	584,920	Up 511.3
General and administrative	2,038,721	527,365	Up 286.6
Loss from Operations	-5,464,508	-1,112,285	Deterioration 391.3
Other Income (Expense)			
Other income (expense)	-25,637	-7,100	Deterioration 261.1
Interest income (expense)	67,622	-22,017	Recovery
Total Other Income (Expense)	41,985	-29,117	Recovery
Loss Before Income Taxes	-5,422,523	-1,141,402	Deterioration 375.1
Income tax provision			
Net Loss	-5,422,523	-1,141,402	Deterioration 375.1
Basic and diluted loss per share	-28.0c	-84.0c	Reduced 66.7
Weighted average shares	19,578,733	1,366,705	Up 1,332.6

BALANCE SHEET

Currency in USD	2014-06-30	2013-12-31	Change %
Assets			
Current Assets			
Cash and cash equivalents	34,564,871	51,803,716	Down 33.3
Short term investments	40,839,020		
Prepaid expenses and other current assets	848,285	671,373	Up 26.4
Total current assets	76,252,176	52,475,089	Up 45.3
Fixed Assets - Net	2,529,229	830,706	Up 204.5
Long term investments	19,742,553		
Other Assets	63,045	13,045	Up 383.3
	98,587,003	53,318,840	Up 84.9
Liabilities and Stockholders' Equity			
Current Liabilities			
Accounts payable	1,987,766	811,600	Up 144.9
Accrued expenses and other liabilities	1,602,916	590,235	Up 171.6
Note payable, current portion	1,525,442		
Warrant liability	181,800	129,400	Up 40.5
Total current liabilities	5,297,924	1,531,235	Up 246.0
Note payable, net of current portion and discount	7,572,021	8,950,000	Down 15.4
Other liabilities	1,050,000	1,050,000	Steady
Total liabilities	13,919,945	11,531,235	Up 20.7
Commitments and Contingencies			

Financial Results (Quarterly) (continued)

30 June, 2014

Stockholders' Equity

Preferred Stock.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding	1,958	1,393	Up 40.6
Common Stock.0001 par value; 150,000,000 shares authorized 19,579,588 and 13,934,876 shares issued and outstanding, respectively			
Additional paid-in capital	109,761,792	57,359,152	Up 91.4
Deficit accumulated during the development stage	-25,102,254	-15,572,940	Deterioration 61.2
Accumulated other comprehensive income	5,562		
Total stockholders' equity	84,667,058	41,787,605	Up 102.6
	98,587,003	53,318,840	Up 84.9

PERFORMANCE RATIOS

	2014-06-30	2013-06-30	Change %
Return on Equity(%)	-11.26	-5.16	Deterioration 118.1
Return on Assets(%)	-9.67	-4.04	Deterioration 139.0

PER SHARE FIGURES

	2014-06-30	2013-06-30	Change %
EPS	-56.0c	-213.0c	Reduced 73.7

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.
